Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).

Alessandro D Santin,Virginia Filiaci,Stefania Bellone,Elena S Ratner,Cara A Mathews,Guilherme Cantuaria,Camille C Gunderson,Teresa Rutledge,Barbara M Buttin,Heather A Lankes,Michael Frumovitz,Samir N Khleif,Warner K Huh,Michael J Birrer

Gynecologic Oncology Reports（2020）

引用 13|浏览99

暂无评分

摘要

•Endometrial cancer commonly harbors hotspot mutations in the PIK3CA gene.•NRG-GY008 evaluated the activity of copanlisib, an inhibitor of PIK3CA, in recurrent endometrial cancer patients.•Copanlisib has an acceptable safety profile but low antitumor activity in endometrial cancer.•Combinations of copanlisib may be necessary to increase clinical responses in endometrial cancer patients.

查看译文

关键词

Endometrial neoplasms,Copanlisib,Pik3ca,Targeted treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要